title: Pleural effusions following endoscopic injection sclerotherapy for cirrhotic patients with esophageal varices.
abstract: OBJECTIVE
  Endoscopic injection sclerotherapy is in widespread use for patients with esophageal varices. It is well known that pleural effusions are among complications following endoscopic sclerotherapy. However, there are few studies regarding the proportion of patients developing pleural effusions after sclerotherapy.
  
  
  METHODS
  Between August 1991 and September 1998, 575 endoscopic injection sclerotherapies were carried out in 128 patients. Chest radiographs were obtained prior to and 24 hours after all procedures. We also obtained other clinical data from all patients.
  
  
  RESULTS
  In total, 17.7% of post-sclerotherapy patients were diagnosed as having small amounts of pleural effusions. Logistic regression revealed pleural effusions after sclerotherapy to be associated with ascites, chest pain for 24 hours, total volume of sclerosant and submucosal injection of more than 4mL of sclerosant. In parallel with injection of an increasing amount of submucosal sclerosant, the proportion of patients with pleural effusion increased.
  
  
  CONCLUSIONS
  Pleural effusions were related to ascites, chest pain for 24 hours, total sclerosant volume and submucosal injection of sclerosant.
authors.affiliation: Third Department of Internal Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan.
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Kayama
authors.forename: Masahiko
authors.initials: M
authors.lastname: Inamori
authors.forename: Jun-ichi
authors.initials: J
authors.lastname: Togawa
authors.forename: Takeshi
authors.initials: T
authors.lastname: Shimamura
authors.forename: Yoko
authors.initials: Y
authors.lastname: Tokita
authors.forename: Tadashi
authors.initials: T
authors.lastname: Umezawa
authors.forename: Takashi
authors.initials: T
authors.lastname: Sakaguchi
authors.forename: Makoto
authors.initials: M
authors.lastname: Naitoh
authors.forename: Hajime
authors.initials: H
authors.lastname: Nagase
authors.forename: Atsushi
authors.initials: A
authors.lastname: Nakajima
authors.forename: Toshifumi
authors.initials: T
authors.lastname: Saito
authors.forename: Shizuo
authors.initials: S
authors.lastname: Tominaga
authors.forename: Norio
authors.initials: N
authors.lastname: Ueno
authors.forename: Katsuaki
authors.initials: K
authors.lastname: Tanaka
authors.forename: Hisahiko
authors.initials: H
authors.lastname: Sekihara
mesh_terms: D001201:Ascites / Q000209:etiology; D002637:Chest Pain / Q000209:etiology; D004724:Endoscopy / Q000009:adverse effects; D004932:Esophageal and Gastric Varices / Q000628:therapy*; D005260:Female; D006801:Humans; D007267:Injections / Q000009:adverse effects; D008103:Liver Cirrhosis / Q000628:therapy*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009829:Oleic Acids / Q000008:administration & dosage / Q000009:adverse effects; D010996:Pleural Effusion / Q000209:etiology*; D012189:Retrospective Studies; D012597:Sclerosing Solutions / Q000008:administration & dosage / Q000009:adverse effects; D015911:Sclerotherapy / Q000009:adverse effects*
chemical_list: D009829:Oleic Acids; D012597:Sclerosing Solutions; C033343:ethanolamine oleate